Immunovant (IMVT) Receivables - Net (2021 - 2026)
Immunovant's (IMVT) quarterly Receivables - Net came in at $1.1 million in Q1 2026, down 45.63% YoY from $2.1 million in Q1 2025, and down 31.04% on a QoQ basis from $1.6 million in Q4 2025.
Immunovant (IMVT) Receivables - Net (2021 - 2026) Analysis & Trends
Immunovant (IMVT) has 6 years of Receivables - Net data on file, last reported at $1.1 million in Q1 2026.
- Quarterly Receivables - Net fell 45.63% year-over-year to $1.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.1 million (down 45.63% YoY) and the FY2026 annual result came in at $1.1 million, down 45.63% from the prior year.
- Receivables - Net retreated to $1.1 million in Q1 2026, from $1.6 million in the prior quarter.
- In the past five years, Receivables - Net ranged from a high of $13.2 million in Q2 2022 to a low of $700000.0 in Q1 2023.
- A 5-year average of $3.2 million and a median of $1.9 million in 2025 frame the typical range for Receivables - Net.
- Annual changes were most pronounced in 2022 — Receivables - Net surged 1951.85% — and 2023, when it sank 94.28%.
- Tracing IMVT's Receivables - Net over 5 years: stood at $704000.0 in 2022, then jumped by 46.16% to $1.0 million in 2023, then surged by 116.13% to $2.2 million in 2024, then declined by 26.12% to $1.6 million in 2025, then slumped by 31.04% to $1.1 million in 2026.
- The last three Receivables - Net figures came in at $1.1 million (Q1 2026), $1.6 million (Q4 2025), and $2.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Immunovant | 8.63 Bn | 7.83 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 697,000.00 |
| Jun 30, 2026 | 697,000.00 |
| Mar 31, 2026 | 1.13 Mn |
| Mar 31, 2026 | 1.13 Mn |
| Dec 31, 2025 | 1.64 Mn |
| Dec 31, 2025 | 1.64 Mn |
| Sep 30, 2025 | 1.97 Mn |
| Sep 30, 2025 | 1.97 Mn |
| Jun 30, 2025 | 1.94 Mn |
| Jun 30, 2025 | 1.94 Mn |
| Mar 31, 2025 | 2.08 Mn |
| Mar 31, 2025 | 2.08 Mn |
| Dec 31, 2024 | 2.22 Mn |
| Dec 31, 2024 | 2.22 Mn |
| Sep 30, 2024 | 1.88 Mn |
| Sep 30, 2024 | 1.88 Mn |
| Jun 30, 2024 | 2.42 Mn |
| Jun 30, 2024 | 2.42 Mn |
| Mar 31, 2024 | 5.34 Mn |
| Mar 31, 2024 | 5.34 Mn |